{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:48:14Z","timestamp":1792615694524,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07723-z","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:34:24Z","timestamp":1770136464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Fu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaihu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"11","key":"7723_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321","journal-title":"Cancer Res"},{"issue":"8","key":"7723_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354","journal-title":"Cell"},{"issue":"1","key":"7723_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348","journal-title":"CA Cancer J Clin"},{"issue":"9791","key":"7723_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320","journal-title":"Lancet"},{"issue":"18","key":"7723_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703","journal-title":"N Engl J Med"},{"key":"7723_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na\u2019ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55\u201368","journal-title":"Drug Resist Updat"},{"issue":"4","key":"7723_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41419-022-04799-5","volume":"13","author":"T Qin","year":"2022","unstructured":"Qin T, Xiao Y, Qian W, Wang X, Gong M, Wang Q, et al. HGF\/c-met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR\/NGF axis. Cell Death Dis. 2022;13(4):387","journal-title":"Cell Death Dis"},{"key":"7723_CR8","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"7723_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350","journal-title":"Nat Med"},{"key":"7723_CR10","doi-asserted-by":"publisher","first-page":"110932","DOI":"10.1016\/j.msec.2020.110932","volume":"112","author":"D Lee","year":"2020","unstructured":"Lee D, Cha C. Cell subtype-dependent formation of breast tumor spheroids and their variable responses to chemotherapeutics within microfluidics-generated 3D microgels with tunable mechanics. Mater Sci Eng C Mater Biol Appl. 2020;112:110932","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"21","key":"7723_CR11","doi-asserted-by":"publisher","first-page":"2002002","DOI":"10.1002\/advs.202002002","volume":"7","author":"Y Wang","year":"2020","unstructured":"Wang Y, Kankala RK, Zhang J, Hao L, Zhu K, Wang S, et al. Modeling endothelialized hepatic tumor microtissues for drug screening. Adv Sci (Weinh). 2020;7(21):2002002","journal-title":"Adv Sci (Weinh)"},{"key":"7723_CR12","doi-asserted-by":"crossref","unstructured":"He J, Chen C, Chen L, Cheng R, Sun J, Liu X, et al. Honeycomb-like hydrogel microspheres for 3D bulk construction of tumor models. Res (Washington, D.C.). 2022, 2022;9809763","DOI":"10.34133\/2022\/9809763"},{"issue":"3","key":"7723_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gutjnl-2016-313133","volume":"67","author":"ES Knudsen","year":"2018","unstructured":"Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. 2018;67(3):508\u201320","journal-title":"Gut"},{"key":"7723_CR14","doi-asserted-by":"crossref","unstructured":"Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to Gemcitabine. Cancers (Basel). 2017;9(11)","DOI":"10.3390\/cancers9110157"},{"issue":"3","key":"7723_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nm.4038","volume":"22","author":"EM Noll","year":"2016","unstructured":"Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med. 2016;22(3):278\u201387","journal-title":"Nat Med"},{"issue":"12","key":"7723_CR16","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-19-3975","volume":"27","author":"G Yang","year":"2021","unstructured":"Yang G, Guan W, Cao Z, Guo W, Xiong G, Zhao F, et al. Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models. Clin Cancer Res. 2021;27(12):3383\u201396","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7723_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/1078-0432.CCR-07-2247","volume":"14","author":"MP Kim","year":"2008","unstructured":"Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 2008;14(5):1284\u201385","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7723_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","volume":"26","author":"NA Nicola","year":"2015","unstructured":"Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015;26(5):533\u201344","journal-title":"Cytokine Growth Factor Rev"},{"key":"7723_CR19","doi-asserted-by":"crossref","unstructured":"Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, et al. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019;10","DOI":"10.1038\/s41467-019-11044-9"},{"issue":"7754","key":"7723_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","volume":"569","author":"Y Shi","year":"2019","unstructured":"Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019;569(7754):131\u201335","journal-title":"Nature"},{"key":"7723_CR21","doi-asserted-by":"crossref","unstructured":"Ye J, Qin SS, Hughson AL, Hannon G, Vrooman TG, Lesch ML, et al. Blockade of LIF and PD-L1 enhances chemotherapy in preclinical PDAC models. Cancers (Basel). 2025;17(2)","DOI":"10.3390\/cancers17020204"},{"issue":"1","key":"7723_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41698-024-00612-y","volume":"8","author":"B Ebrahimi","year":"2024","unstructured":"Ebrahimi B, Viswanadhapalli S, Pratap UP, Rahul G, Yang X, Pitta Venkata P, et al. Pharmacological inhibition of the LIF\/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis. NPJ Precis Oncol. 2024;8(1):118","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"7723_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1517\/14728222.2013.830105","volume":"17","author":"S Xu","year":"2013","unstructured":"Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013;17(11):1303\u201328","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"7723_CR24","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1038\/s41467-021-27103-z","volume":"12","author":"HL Svilenov","year":"2021","unstructured":"Svilenov HL, Sacherl J, Protzer U, Zacharias M, Buchner J. Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design. Nat Commun. 2021;12(1):6737","journal-title":"Nat Commun"},{"key":"7723_CR25","doi-asserted-by":"publisher","first-page":"119744","DOI":"10.1016\/j.biomaterials.2019.119744","volume":"232","author":"V Brancato","year":"2020","unstructured":"Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Could 3D models of cancer enhance drug screening? Biomaterials. 2020;232:119744","journal-title":"Biomaterials"},{"key":"7723_CR26","doi-asserted-by":"crossref","unstructured":"Boj SF, Hwang CI, Baker LA, Chio E II, Corbo DD, V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1\u20132):324\u201338","DOI":"10.1016\/j.cell.2014.12.021"},{"key":"7723_CR27","doi-asserted-by":"crossref","unstructured":"Novotny J, Strnadov\u00e1 K, Dvor\u00e1nkov\u00e1 B, Kocourkov\u00e1 S, Jaksa R, Dundr P, et al. Single-cell RNA sequencing unravels heterogeneity of the stromal niche in cutaneous melanoma heterogeneous spheroids. Cancers. 2020;12(11)","DOI":"10.3390\/cancers12113324"},{"issue":"4","key":"7723_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","volume":"15","author":"S Penuelas","year":"2009","unstructured":"Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315\u201327","journal-title":"Cancer Cell"},{"key":"7723_CR29","doi-asserted-by":"publisher","first-page":"107754","DOI":"10.1016\/j.pharmthera.2020.107754","volume":"221","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu J, Wang J, Hu W, Feng Z. The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther. 2021;221:107754","journal-title":"Pharmacol Ther"},{"key":"7723_CR30","doi-asserted-by":"crossref","unstructured":"Spencer N, Rodriguez Sanchez AL, Gopalam R, Subbarayalu P, Medina DM, Yang X, et al. The LIFR inhibitor EC359 effectively Targets type II Endometrial cancer by blocking LIF\/LIFR Oncogenic signaling. Int J Mol Sci. 2023;24(24)","DOI":"10.3390\/ijms242417426"},{"key":"7723_CR31","doi-asserted-by":"crossref","unstructured":"Blankenship L, Pratap UP, Yang X, Liu Z, Altwegg KA, Santhamma B, et al. Inhibition of LIFR blocks adiposity-driven endometrioid endometrial cancer growth. Cancers (Basel). 2022;14(21)","DOI":"10.3390\/cancers14215400"},{"issue":"8","key":"7723_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1535-7163.MCT-18-1258","volume":"18","author":"S Viswanadhapalli","year":"2019","unstructured":"Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, et al. EC359: a first-in-class small-molecule inhibitor for targeting Oncogenic LIFR signaling in triple-negative breast cancer. Mol Cancer Ther. 2019;18(8):1341\u201354","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"7723_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41698-025-01046-w","volume":"9","author":"R Bhatia","year":"2025","unstructured":"Bhatia R, Khan I, Li X, Gautam S, Seshacharyulu P, Alsafwani ZW, et al. Targeting cancer-associated fibroblast-driven LIF\/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. NPJ Precis Oncol. 2025;9(1):296","journal-title":"NPJ Precis Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07723-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07723-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:16:05Z","timestamp":1772622965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07723-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7723"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07723-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (21\/197\u20132868) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent prior to study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors agree to submit the research article for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N. Z. is an employee of Hsienseng Medical Technology Co. Ltd. All other authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}